Metallopharmaceutical complexes based on vanadium as potential anti-hyperglycemic agents | ||
| Egyptian Journal of Chemistry | ||
| Article 3, Volume 63, Issue 2, February 2020, Pages 389-404 PDF (1.43 M) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/ejchem.2019.13511.1837 | ||
| Authors | ||
| Ramy Mohamed Abd Elaziz* 1; Abdu Saad El Tabl2; Mohamed Mohey Elmazar3; Moshira Abd Elwahed4 | ||
| 1Biochemistry,faculty of pharmacy,The British University in Egypt | ||
| 2Chemistry,faculty of science,Menoufia University,Egypt | ||
| 3Pharmacology,faculty of pharmacy, The British university in Egypt | ||
| 4Pathology,faculty of medicine,Menoufia University,Egypt | ||
| Abstract | ||
| Interaction between vanadium pentoxide and bioactive Schiff–bases led to the formation of vanadium (III/IV) complexes. Ten complexes have been characterized using mass, IR, UV-VIS and ESR spectra, magnetic moments and conductance measurements as well as elemental and thermal analyses. Magnetic moments and ESR measurements confirmed vanadium complexes have (III/IV) oxidation state. Conductivity measurements indicate that complexes are not electrolytes. A representative set of vanadium (III/IV) complexes in varying coordination environments have been tested as anti-hyperglycemic agents against type 2 diabetes mellitus in concentration doses (30 and 100 µM/Kg) using female albino rats. The pharmacological data showed that, complexes 1 and 8 produced significant decrease in blood glucose level. Furthermore, these two complexes showed an improvement in liver and kidney function after daily administration for two weeks. | ||
| Keywords | ||
| vanadium complexes; ESR; spectra; magnetism; pathological; Type 2 Diabetes; anti-hyperglycemic | ||
|
Statistics Article View: 817 PDF Download: 550 |
||
